Moderna (MRNA) CFO reports RSU vesting, tax-withheld shares on Form 4
Moderna's CFO, James M. Mock, reported routine stock compensation activity involving Restricted Stock Units (RSUs). On July 2, 2026, 1,452 RSUs converted into common shares, and 703 shares were withheld at an effective price of $72.50 per share to cover tax obligations. After these transactions, Mock directly holds 66,436 common shares and 1,454 RSUs, indicating he retained most of the vested shares.
Beam Therapeutics stock hits 52-week high at 36.89 USD
Beam Therapeutics Inc. (BEAM) stock has surged to a new 52-week high of $36.89, currently trading at $37.02, reflecting a 90.88% increase over the past year. This growth is attributed to investor confidence in its genetic medicine approaches and recent positive developments, including FDA clearance for BEAM-304 and promising clinical data from BEAM-302 and BEACON trials. Analysts like H.C. Wainwright have reiterated a "Buy" rating with an $80.00 price target, highlighting the company's progress and strategic initiatives.
Western Digital Stock Draws Aggressive AI-Boom Price Targets
Western Digital (WDC) stock is drawing aggressive price targets from Wall Street analysts due to an AI-driven infrastructure boom. Firms like Cantor Fitzgerald, BofA, and Melius Research have significantly raised their targets, some to over $1,000, citing increased demand for AI storage and tight hard disk drive supply. Despite a recent tech selloff and insider activity lacking clear signals, the company shows strong financials, though volatility remains high for traders.
Moderna stock hits 52-week high at 81.42 USD
Moderna's stock has reached a 52-week high of $81.42, driven by investor confidence in its mRNA technology and recent advancements in its pipeline. Despite this surge and a 169.2% increase over the past year, InvestingPro data suggests the stock is currently overvalued. The company recently announced progress in its in vivo CAR-T program and an FDA advisory committee recommendation for its seasonal influenza vaccine.
Moderna stock hits 52-week high at 81.42 USD By Investing.com
Moderna's stock has reached a new 52-week high of $81.42, reflecting a 169.2% increase over the past year and a 124% gain in the last six months. This surge is attributed to advancements in its mRNA technology, including progress in its CAR-T program for autoimmune diseases and a positive FDA advisory committee recommendation for its seasonal influenza vaccine. Despite its strong performance, InvestingPro data suggests the stock is currently overvalued relative to its Fair Value estimate.
Companies Like SELLAS Life Sciences Group (NASDAQ:SLS) Can Afford To Invest In Growth
This article analyzes SELLAS Life Sciences Group's financial position, specifically its cash reserves and burn rate. It concludes that despite having substantial cash, the company's high burn rate means it can only fund current operations for a little over a year without seeking additional financing.
Cantor Fitzgerald reiterates Amgen stock Neutral rating at $350
Cantor Fitzgerald has reiterated a Neutral rating on Amgen Inc. (NASDAQ:AMGN) with a $350 price target, despite expectations of a strong quarterly earnings driven by Repatha and Uplizna performance. The firm noted that Amgen's pipeline lacks significant drivers to extend its recent stock momentum, which has seen shares rise over 10% since June. While InvestingPro analysis suggests Amgen is undervalued with a Fair Value of $394, Cantor Fitzgerald believes a good earnings report alone won't lead to a substantial re-rating given upcoming patent expirations and other pipeline issues.
Invivyd (NASDAQ: IVVD) faces 2027 end of PEMGARDA COVID EUA
Invivyd (NASDAQ: IVVD) announced that the FDA has issued a Notice of Termination for the Emergency Use Authorization (EUA) of its COVID-19 monoclonal antibody, PEMGARDA, effective June 29, 2027. This follows the HHS's decision to end the COVID-19 EUA declaration. PEMGARDA will remain authorized during a twelve-month transition period, during which Invivyd plans to discuss potential Biologics License Application (BLA) pathways with the FDA for full approval.
17,700 Shares in Moderna, Inc. $MRNA Bought by Louisiana State Employees Retirement System
The Louisiana State Employees Retirement System recently purchased 17,700 shares of Moderna, Inc. ($MRNA) in the first quarter, valued at approximately $899,000, significantly increasing institutional ownership to 75.33%. Despite this, company insiders have been selling shares, totaling 125,088 shares sold in the last 90 days. Analysts maintain a cautious stance, with an average "Reduce" rating and a price target substantially lower than the current trading price.
Price to sales forward of Moderna, Inc. – NASDAQ:MRNA
This article provides financial data for Moderna, Inc. (NASDAQ: MRNA), specifically focusing on its price to sales forward metric. The content highlights a specific period's value and change for this financial indicator, noting that the data is provided by ICE Data Services and FactSet.
Fidelity Health Care vs. State Street Biotech: Which ETF Fits Your Portfolio Best?
This article compares two healthcare ETFs: the Fidelity MSCI Health Care Index ETF (FHLC) and the State Street SPDR S&P Biotech ETF (XBI). FHLC offers broader diversification, lower costs, and higher dividend yield, catering to more conservative investors. XBI, focusing on the biotech subsector, provides higher recent growth but comes with increased volatility and a higher expense ratio, making it suitable for aggressive investors.
The Spikevax XBB.1.5 COVID-19 vaccine - Moderna Inc. bets on updated protection for the US fall seas
Moderna's Spikevax XBB.1.5 COVID-19 vaccine offers updated protection against current Omicron sublineages for the 2024-2025 respiratory season in the United States. It's designed as a seasonal booster, widely available, and supported by robust immunogenicity data. For investors, this vaccine is a key revenue driver, transitioning Moderna's COVID-19 franchise to a commercially-driven model while combination vaccine programs advance.
(MRNA) Risk Channels and Responsive Allocation
This article provides an in-depth analysis of Moderna Inc. (NASDAQ: MRNA) using AI models to determine trading strategies and risk management. It identifies strong sentiment across all horizons, suggesting an overweight bias, and outlines specific position, momentum breakout, and risk hedging strategies with entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strength, support, and resistance levels.
PCVX - Vaxcyte Inc Volatility & Greeks
This article provides a detailed financial overview of Vaxcyte Inc (PCVX), including its stock performance, volatility metrics, and various financial ratios up to July 2nd. It highlights key data such as market capitalization, income, sales, EPS, insider and institutional ownership, and price performance over different periods. The data indicates Vaxcyte's current financial health and market position within the biotechnology sector.
Jim Cramer Turns Bullish on Moderna After 150% Rally, Citing Cancer Pipeline and Flu Vaccine Momentum
Jim Cramer has become bullish on Moderna (MRNA) due to its transformed pipeline, which includes cancer vaccines, a seasonal flu vaccine, and rare disease treatments. Despite a significant first-quarter net loss, the company holds $7.5 billion in cash and aims for breakeven by 2028, with its stock surging 150% in 2026. Cramer advises waiting for a pullback before investing, while analysts like Jefferies maintain a cautious stance, citing that significant flu revenue may not arrive until 2027.
AESI Slides As Atlas Energy Faces Heavy Selling
Atlas Energy Solutions Inc. (AESI) stock fell by 7.36% following news of expanded drilling and production slowdowns. The stock's price slid from over $16 to the mid-$14s, indicating significant selling pressure and profit-taking, despite annual revenues exceeding $1 billion. The company faces challenges with negative earnings, free cash flow, and thin margins, leading analysts to maintain a negative sentiment and suggesting a cautious stance for traders.
Tranche Update on Emerald Holding, Inc.'s Equity Buyback Plan announced on October 5, 2020.
Emerald Holding, Inc. has provided an update on its equity buyback plan, originally announced on October 5, 2020. As of March 31, 2026, the company repurchased no shares during the first quarter, representing 0% for $0 million. The company has now completed its repurchase of 17,523,013 shares, totaling 19.14% of its equity for $71.91 million under this plan.
Jim Cramer Says “For the First Time in Ages, I Like Having a Position in Moderna”
Jim Cramer has expressed renewed interest in Moderna (NASDAQ: MRNA), citing its impressive 146% year-to-date gain and recent product developments, despite the company still being unprofitable. He notes Moderna's strong performance as an outlier among tech hardware companies and believes its rally is real due to new products and a clear roadmap to profitability. Cramer, however, advises investors to wait for a pullback before buying, acknowledging the stock's significant appreciation and the company's financial challenges.
If You Invested $1,000 in Cytomx Therapeutics Inc (CTMX)
This article analyzes the historical performance of a $1,000 investment in Cytomx Therapeutics Inc (CTMX) over different periods, including 1, 5, and 10 years, and since October 2015. It also provides a detailed company profile, outlining CytomX's focus on conditionally activated biologics for oncology, its proprietary PROBODY® platform, clinical pipeline, and collaborations. The data shows significant volatility and overall negative returns over longer periods, contrasting with a strong gain in the last year.
YieldMax MRNA option income strategy ETF announces weekly distribution of $0.3944
The YieldMax MRNA Option Income Strategy ETF has declared a weekly distribution of $0.3944 per share. This announcement provides investors with details regarding the payout from the options income strategy.
$10,000 Became $5,744: The Equal-Weight Rebalancing Tax That WCLD Never Discloses
The article analyzes the performance of the WisdomTree Cloud Computing Fund (WCLD), highlighting that an initial $10,000 investment five years ago would now be worth $5,744, significantly underperforming broader market funds like QQQ. It attributes this underperformance to WCLD's equal-weight rebalancing strategy, which involves selling winning stocks and buying laggards semi-annually, alongside its focus on smaller, higher-beta cloud companies. The author argues this strategy incurs hidden costs through trading friction, opportunity cost compared to major tech ETFs, and tax drag, urging investors to consider cheaper and more established alternatives for cloud exposure.
Moderna Inc. updates mRNA vaccine pipeline. Investors weigh long-term growth prospects
Moderna Inc. is continuing to advance its mRNA-based vaccine and therapeutic pipeline, building on its success with the COVID-19 vaccine. The company's strategy centers on its adaptable mRNA platform, which it is applying to infectious diseases, oncology, rare diseases, and autoimmune conditions. Analysts emphasize the significant investment required for research and development, clinical trials, and manufacturing to bring new products to market and sustain long-term growth.
Q1 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks
This article reviews the Q1 2026 earnings for AbbVie and other therapeutics companies, highlighting strong performance across the sector. While AbbVie reported increased revenues and an optimistic outlook, Moderna saw the fastest revenue growth, and United Therapeutics had the weakest performance. The article also touches on shifting market narratives from AI to geopolitical risks, emphasizing the importance of fundamental strength in investments.
How Retirees Can Turn $100,000 Into Steady Monthly Income With This Dividend Stock
Realty Income (O), a monthly dividend payer, offers retirees a way to convert a $100,000 investment into approximately $424 in monthly income, equating to a 5.09% annual yield. The company boasts 670 consecutive monthly dividend payments and has consistently raised its quarterly dividend. Its robust financial performance, including increased AFFO per share and raised investment guidance, supports sustained dividend growth for income-focused investors.
MRNA Stock on the Move: What Sparked the 33.5% Jump in the Past Week?
Moderna's stock (MRNA) jumped 33.5% in the past week, adding nearly $8 billion to its market value, primarily driven by its Science Day event. During this event, Moderna outlined its strategy to expand beyond vaccines into a diversified biotechnology company, leveraging its mRNA platform across oncology, autoimmune diseases, and cell therapy. Investors reacted positively to the company's plans to diversify its therapeutic areas and revenue streams, including the introduction of new research horizons and investigational therapies.
MRNA Stock on the Move: What Sparked the 33.5% Jump in the Past Week?
Moderna's stock surged 33.5% in the past week, adding nearly $8 billion to its market value, following its Science Day presentation. The company outlined a vision to expand its messenger RNA (mRNA) platform beyond vaccines into diverse therapeutic areas such as oncology, autoimmune diseases, and cell therapy. Investors welcomed this strategy, noting the potential for new growth platforms and diversified revenue streams, which helped lift the stock to a 52-week high.
H.C. Wainwright Remains a Buy on Biogen (BIIB)
H.C. Wainwright maintained a Buy rating on Biogen (BIIB) with a price target of $237.00. This rating was echoed by Needham's Ami Fadia, while Morgan Stanley holds a Neutral stance. Biogen reported increased quarterly revenue and net profit in its latest earnings release for Q1, ending March 31, 2026.
This 65-Year Dividend Streak Nearly Broke. Here Is Why It Keeps Rising
Cincinnati Financial (CINF) has extended its Dividend King streak to 65 years with an 8% increase in its quarterly dividend, despite nearly breaking the streak after a $90 million net loss in Q1 2025 due to California wildfires. The company rebounded significantly in Q1 2026 with $274 million net income, attributed to strong underwriting discipline, a robust investment portfolio, and a fortress balance sheet. CINF has outperformed the S&P 500 significantly over the past decade, demonstrating its strength as a compounding machine for investors.
Argenx SE outlines growth path in rare disease therapies
Argenx SE, a biotechnology company, is focusing on building a global franchise in autoimmune and rare disease treatments using antibody-based therapies. The company aims to expand its presence in major markets, including the United States, through a blend of internal research and strategic collaborations. Its strategy emphasizes specialized antibody platforms to address hard-to-treat indications, particularly focusing on autoimmune and neuromuscular diseases, with the goal of shifting revenue from milestones to recurring product sales.
Cerus CFO Kevin Green sells $99,105 in CERS shares
Cerus CFO Kevin Green sold 33,676 shares of CERS stock for $99,105 on June 30, 2026, under a pre-arranged trading plan to cover tax obligations from restricted stock unit vesting, not as a discretionary sale. Following these transactions, Green directly holds 1,062,188 shares. The company, with a $627 million valuation, is currently unprofitable and its stock is trading near a 52-week high after a 103% return in the past year.
Taiwan Semiconductor Manufacturing Company Ltd. $TSM Shares Acquired by Y Intercept Hong Kong Ltd
Y Intercept Hong Kong Ltd significantly increased its stake in Taiwan Semiconductor Manufacturing Company (TSMC) by 273.2% in the first quarter, now holding 81,189 shares worth approximately $27.4 million. This move is part of a broader trend of institutional investors and hedge funds increasing their positions in TSM, which currently has a "Buy" consensus rating from analysts with an average price target of $449.38. TSMC is expanding its 3-nanometer footprint globally, reinforcing its leadership in AI and high-performance computing chips, and recently raised its quarterly dividend to $1.1136 per share.
MRNA - Moderna Inc Latest SEC Filings
This article provides the latest SEC filing information for Moderna Inc. (MRNA), including a comprehensive financial overview, key performance indicators, stock statistics, and analyst recommendations. It details the company's financial health, insider and institutional ownership, and recent stock performance.
West Pharmaceutical Services Stock 10-Day Winning Spree: Stock Climbs 13%
West Pharmaceutical Services (WST) has experienced a 10-day winning streak, with its stock climbing 13% and its market cap increasing by $3.0 billion. Despite this strong performance, the stock is considered "Relatively Expensive" due to its "Very High valuation," suggesting that while operating performance is strong, the current price may not be an immediate buying opportunity. The article also provides a comparison of WST stock returns against the S&P 500 and highlights the Trefis High Quality Portfolio for outperforming benchmarks.
Creative realities CFO Koshewa buys $99,998 in company stock
Tamra L. Koshewa, CFO of Creative Realities, Inc., purchased 28,571 shares of company stock for $99,998 on June 30, 2026. This transaction indicates insider confidence, especially as the stock has seen significant gains year-to-date and recently joined the Russell 3000 Index. Despite the stock being considered slightly overvalued by InvestingPro, the purchase aligns with positive recent news for the company, including revenue growth and a public offering.
Cadrenal Therapeutics CEO sells $22,422 in stock
Cadrenal Therapeutics CEO Pham Quang X sold 7,400 shares of company stock worth $22,422 on June 29, 2026, under a pre-arranged trading plan. Despite the insider sale and a significant year-over-year stock price drop, InvestingPro analysis suggests the stock is undervalued. The company also recently announced a private placement, and clinical data for its drug candidate CAD-1005 has been accepted for presentation.
Moderna (NASDAQ:MRNA) gains $2.9 billion as investors pile into flu push, beating 2025 revenue
Moderna's stock (NASDAQ:MRNA) surged, adding $2.9 billion in market capitalization, as investor enthusiasm for its flu vaccine candidate, mFlusiva, drove shares up 10.2%. This increase follows FDA advisers' support for the vaccine, with the market cap gain significantly surpassing Moderna's anticipated 2025 revenue. Despite the market uplift, analysts like Citi's Geoff Meacham caution that significant sales from mFlusiva are not expected until late 2027.
Six Flags names Mark Pauls as chief operating officer
Six Flags Entertainment Corporation has appointed Mark Pauls as its new Chief Operating Officer, effective July 15, 2026. Pauls brings nearly five decades of experience in the entertainment industry, having held senior leadership roles at Herschend Family Entertainment, Palace Entertainment, SeaWorld Parks, and Busch Gardens. This appointment is part of Six Flags' ongoing efforts to enhance operational excellence and improve performance, following other recent developments including new analyst ratings and a CFO appointment.
Moderna stock jumps as pipeline progress and flu shot data lift sentiment
Moderna (MRNA) stock soared 9.2% after a positive FDA advisory panel recommendation for its flu vaccine mRNA-1010/mFLUSIVA and promising updates on its broader pipeline, which includes oncology and autoimmune programs. Analysts remain optimistic about the company's long-term prospects, with Piper Sandler raising its price target, despite ongoing losses as Moderna invests heavily in R&D. The company's strong cash reserves of $5.21 billion are expected to support its extensive product development efforts.
U.S. Indexes Closed Mixed Thursday As Genuine Parts Led, Vicor Lagged
U.S. stock indexes closed mixed on Thursday, with the Dow Jones Industrial Average gaining 1.14%. In contrast, the S&P 500 Index remained flat, and the NASDAQ Composite Index saw a decline of 0.80%. The article highlights Genuine Parts (GPC) as a leader and Vicor (VICR) as a laggard.
Jazz Pharmaceuticals stock hits all-time high at 243.39 USD
Jazz Pharmaceuticals (JAZZ) stock has reached an all-time high of $243.46, trading just below its 52-week high of $243.32, marking a 132% surge from its 52-week low. This strong performance, reflected in a 121.3% one-year change, is supported by the company's impressive 91.5% gross profit margin and strong cash flow, with analysts considering it undervalued. Despite a setback with its lung cancer drug Zepzelca not meeting primary endpoints in a Phase 3 trial, BofA Securities raised its price target for Jazz Pharmaceuticals, citing increased revenue growth from its Ziihera product.
AbbVie Inc Stock (ABBV) Moved Up by 3.44% on Jul 2: Drivers Behind the Movement
AbbVie Inc (ABBV) stock rose by 3.44% on July 2, driven by several key factors. Proposed changes to the 340B Drug Pricing Program are expected to benefit major drug developers like AbbVie by improving profit margins. Additionally, the company's acquisition of Apogee Therapeutics has been well-received, strengthening its immunology pipeline, and the FDA approval for Skyrizi's pediatric use significantly expands its market reach.
Amgen Inc Stock (AMGN) Moved Up by 3.01% on Jul 2: Key Drivers Unveiled
Amgen Inc. (AMGN) saw a 3.01% increase in its stock price on July 2, primarily driven by a federal judge's preliminary injunction blocking a proposed price cap on its key drug, Enbrel. This legal victory overshadowed concerns regarding data integrity for Tavneos and a Class II recall of Corlanor. Analysts remain optimistic about Amgen's long-term potential, focusing on pipeline drugs like MariTide and olpasiran, despite existing regulatory challenges and a leveraged balance sheet.
Canopy Growth CGC Stock Builds Turnaround Momentum After FY2026 Reset
Canopy Growth (CGC) is showing signs of a turnaround, with its core cannabis business returning to top-line growth in FY2026, driven by gains in Canadian adult-use, medical, and international cannabis revenue. The company also improved its balance sheet by shifting to a net cash position of $131.3M following the MTL Cannabis acquisition, which made it the largest medical cannabis provider in Canada. Despite ongoing net losses and compressed gross margins, management is guiding for positive adjusted EBITDA in FY2027, making CGC a watch list stock for active traders looking for turnaround plays.
MRNA Stock Surges As Flu Win And CAR-T Hype Fuel Breakout
Moderna Inc. (MRNA) stock is surging by 8.25% due to strong pipeline progress, particularly an FDA panel’s unanimous backing of its mRNA-1010/mFLUSIVA flu shot for adults. This regulatory win and hype around in vivo CAR-T programs at Science Day are fueling investor optimism. While the balance sheet is solid, the company is still burning cash, indicating that current trading is driven by catalysts and future potential rather than immediate earnings.
Guardant Health stock rating reiterated at Buy by TD Cowen on UnitedHealth coverage
TD Cowen has reiterated a Buy rating and a $127.00 price target for Guardant Health (NASDAQ:GH) following UnitedHealth's decision to cover the Shield colorectal cancer screening test. This coverage, effective August 1, 2026, for average-risk individuals aged 45-85, is expected to expand Shield's addressable market by approximately 17%. While Guardant Health has a high revenue growth rate, it remains unprofitable, and several other analysts have also raised their price targets on the company.
CIFR Stock Slips As Insider Files Form 144 Sale
Cipher Digital Inc. (CIFR) stock has dropped over 12% following reports of a cybersecurity breach and an insider filing a Form 144 to sell restricted shares. The stock has been on a sharp decline, falling from nearly $30 to around $19.97. This insider selling, combined with the stock's existing volatility and negative financial performance, is increasing short-term tactical trading and making the stock a key watch for momentum and short-bias traders.
Novartis AG Stock (NVS) Moved Up by 3.39% on Jul 2: A Full Analysis
Novartis AG (NVS) saw its stock rise by 3.39% on July 2, driven by the European Commission's authorization of its gene therapy Itvisma for 5q spinal muscular atrophy and boosted price targets from Wall Street firms. This approval expands Novartis's gene therapy footprint, addressing unmet medical needs and offsetting challenges from generic competition. Despite facing patent cliffs and increased debt from M&A, the company's strong pipeline and robust cash flow support its growth.
MRNA Stock Surges As Flu Win And CAR-T Hype Ignite Rally
Moderna Inc. (MRNA) stock surged over 7% after its flu shot received unanimous FDA advisory backing and the company revealed significant pipeline progress in oncology and autoimmune disease, including an in vivo CAR-T program. This positive news, especially regarding the diversification beyond COVID-19 and the potential for a new flu franchise, has ignited investor optimism and sharp price movements. While the company's financials still show losses, its strong cash position provides room for continued development, making it a battleground stock for active traders.
Eli Lilly and Co Stock (LLY) Moved Up by 3.06% on Jul 2: What Signal Does It Send?
Eli Lilly and Co's stock (LLY) surged by 3.06% on July 2, driven by several key developments. These include the launch of a Medicare GLP-1 Bridge program to expand access to Zepbound and Foundayo, the FDA selecting Lilly's Indiana facility for a pilot program to accelerate manufacturing approvals, and European regulators recommending approval for Jaypirca. These strategic advancements and positive market sentiment are fueling investor confidence despite high valuation multiples and industry pricing headwinds.
Pfizer Comirnaty from Pfizer Inc. - updated COVID vaccine leans into fall booster demand
Pfizer's updated Comirnaty COVID-19 vaccine for 2024-2025 targets Omicron XBB-lineage variants and is a key component of the U.S. fall booster campaign. The article details its distribution, pricing shifts from government to commercial channels, and highlights its role as a significant, though no longer dominant, product in Pfizer's diversified portfolio. It also covers practical aspects from pharmacy operations to investor considerations.
